Biotech Archives - Page 58 of 795

1 minute read

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study

April 24, 10:06 AM

Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ETSOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/

IDYA

1 minute read

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted For Presentation At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

April 24, 10:05 AM

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics,

HOWL

1 minute read

CG Oncology To Unveil Results On Cretostimogene In Combination With Pembrolizumab At ASCO 2024

By Benzinga Newsdesk

April 24, 10:04 AM

CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today

CGON

1 minute read

Autolus Therapeutics Announces Abstract For Longer-Term Follow-Up And Additional Data Analysis Of Pivotal Phase 2 FELIX Study Of obe-cel For Adult r/r B-ALL Selected For An Oral Presentation At ASCO

By Benzinga Newsdesk

April 24, 10:04 AM

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional

AUTL

1 minute read

Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection In Cancer Validated By Cas9-Directed Nanopore Sequencing

By Benzinga Newsdesk

April 24, 8:14 AM

Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional

BNGO

1 minute read

CalciMedica Announces Last Patient Enrolled In Phase 2b CARPO Trial Of Auxora In Acute Pancreatitis; Full Target Enrollment Of 216 Patients Achieved

By Benzinga Newsdesk

April 24, 8:08 AM

Full target enrollment of 216 patients achieved Topline data from CARPO expected in 2Q 2024 LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage

CALC

2 minute read

Pasithea Therapeutics Announces The First Cohort Has Completed The Initial Dosing In Its Phase 1 Trial Evaluating PAS-004 In RAS, NF1 And RAF Mutated Cancers

By Benzinga Newsdesk

April 24, 8:05 AM

Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type

KTTA

1 minute read

FDA Approves Novartis’ Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

By Vandana Singh

April 23, 3:05 PM

Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by robust trial data.

NVS

2 minute read

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends

By Vandana Singh

April 23, 3:03 PM

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.

INCY

2 minute read

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown

By Vandana Singh

April 23, 3:00 PM

Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.

BNTX